Rhythm Pharmaceuticals Inc
(NAS:RYTM)
$
53.65
0.47 (0.88%)
Market Cap: 3.28 Bil
Enterprise Value: 3.08 Bil
PE Ratio: 0
PB Ratio: 83.81
GF Score: 61/100 Rhythm Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023 / 04:55PM GMT
Release Date Price:
$25.8
(+3.61%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
For this session, we have Rhythm Pharmaceuticals CEO, David Meeker. Welcome, David.
David P. Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President & CEO
Thank you, Jeff.
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
So maybe for those who are not as familiar with Rhythm, can you just provide a brief introduction?
David P. Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President & CEO
Yes. So Rhythm is a company that's focused on this pathway in our brain,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)